Inivata, a leader in liquid biopsy, has announced the publication of results of a clinical validation and real-world utility study of its InVision® amplicon-based technology for use in advanced non-small cell lung cancer (NSCLC).
The study was conducted in collaboration with Gustave Roussy, a premier European Cancer Centre, and the data have been published in JCO Precision Oncology .
In the study, Inivata’s liquid biopsy test was able to obtain a molecular profile in a significantly higher proportion of patients than through tissue testing, enhancing the potential to access beneficial personalised treatment. The InVision liquid biopsy test, featuring 36 genes most relevant to lung cancer, demonstrated excellent sensitivity, specificity and concordance with tissue biopsy profiles.
Clive Morris, Chief Executive Officer at Inivata, said, “These data add to the growing body of evidence supporting the validation and utility of Inivata’s InVision liquid biopsy platform. It provides clinicians with accurate, reliable genomic information which can guide treatment decisions in patients where standard of care tissue testing is unable to so. We are proud to have worked closely with Gustave Roussy – a world-renowned cancer center – on this important study.”
Prof. Benjamin Besse, Chairman of the cancer medicine department at Gustave Roussy, said: “In this study, the use of the liquid biopsy enabled patients to receive personalized treatments in the absence of a successful tissue biopsy, highlighting its potential to make a meaningful difference to cancer care. Although they cannot cover every biomarker and can’t give a diagnosis of cancer, liquid biopsies are easy to manage in a real world setting and I foresee a future where they become the standard upfront approach to diagnosis and monitoring of NSCLC, sparing patients painful and invasive tissue biopsies.”